Skip to main content

Month: August 2021

Trevena Reports Second Quarter 2021 Results

Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led trial evaluating TRV027 currently enrolling COVID-19 patients Cleveland Clinic outcomes study investigating potential benefit of OLINVYK on respiratory, GI, and cognitive function on track to enroll patients in Q3 TRV045 IND filing for diabetic neuropathic pain on track for Q3 $91M cash at Q2 funds operations through YE 2022 — Company to host conference call today, August 12th, 2021, at 8:00 a.m. ET — CHESTERBROOK, Pa., Aug. 12, 2021 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders,...

Continue reading

Report 2021, Shingles Vaccine Market Size, Share, Growth, Trends, Competitive Analysis, Revenue, Forecast

Key Prominent Players Covered in the Shingles Vaccine Market Research Report Are Merck & Co. Inc., GlaxoSmithKline plc, SK Bioscience and other key market players. Pune, India, Aug. 12, 2021 (GLOBE NEWSWIRE) — The global shingles vaccine market size is projected to experience dynamic growth in the forthcoming years owing to the rising number of ageing population across the world, finds Fortune Business Insights™ in its report, titled “Shingles Vaccine Market, 2021-2028”. Shingles is a disease caused due to the virus known as varicella-zoster. Shingles is a reactivation of the chickenpox in the human body, which can cause a painful rash. There has been a rising prevalence of shingles among the adults and ageing population around the world owing to the re-occurrence of varicella-zoster virus in the human body. Thus, this is...

Continue reading

Brookfield Reinsurance Announces Second Quarter Results and Regular Distribution

BROOKFIELD, NEWS, Aug. 12, 2021 (GLOBE NEWSWIRE) — Brookfield Asset Management Reinsurance Partners Ltd. (“Brookfield Reinsurance”) (NYSE, TSX: BAMR) today announced financial results for the quarter ended June 30, 2021. Sachin Shah, CEO of Brookfield Reinsurance, stated, “We are pleased to report our first quarterly earnings since the launch of Brookfield Reinsurance as a public company. We were established by Brookfield to own and operate a diversified insurance and reinsurance portfolio and are a paired security to BAM’s Class A Shares. As a result, we benefit significantly from Brookfield’s financial strength and investment capabilities. We are off to a strong start, with agreements to manage $40 billion of insurance assets, and we have significant capital available to deploy into a large pipeline of investment opportunities...

Continue reading

Brookfield Announces $2.4 billion of Net Income, $1.2 billion of Distributable Earnings in Second Quarter

$24 billion of Capital Raised, including $9 billion for our Flagship Property Fund and $7 billion for our Transition Fund BROOKFIELD, NEWS, Aug. 12, 2021 (GLOBE NEWSWIRE) — Brookfield Asset Management Inc. (NYSE: BAM, TSX: BAM.A) today announced financial results for the quarter ended June 30, 2021. Nick Goodman, CFO of Brookfield, stated, “Our business performed very well during the quarter, recording $1.2 billion of distributable earnings. Growth in our asset management franchise, steady returns on our principal investments and continued momentum on our capital recycling initiatives all contributed to the strong quarter. Subsequent to quarter end, we held the first close of $9 billion for our fourth flagship real estate fund, and our $7 billion founders’ close for our Global Transition Fund, taking total fundraising since last...

Continue reading

KULR Technology Group to Present at the Q3 Virtual Investor Summit

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a leading developer of next-generation lithium-ion battery safety and thermal management technologies, today announced that it will present at the Q3 Virtual Investor Summit, hosted by the Investor Summit Group, on August 18, 2021. Michael Mo, Chief Executive Officer of KULR Technology Group, is scheduled to present on Wednesday, August 18, 2021 at 1:15 p.m. Eastern time and will participate in one-on-one meetings with investors throughout the event. The presentation will be webcast live and available for replay here. An archived webcast of the presentation will be made available at www.investorsummitgroup.com and on KULR’s website at https://kulrtechnology.com/category/presentations. Registration...

Continue reading

Valoe Has Signed a Memorandum of Understanding for Establishing a Joint Venture Company in the Kingdom of Saudi Arabia. Valoe’s Objective is to Deliver a Solar Module Manufacturing Plant it Designs to the Joint Venture.

Valoe Corporation        Inside Information 12 August 2021 at 13.35 (Finnish time) Valoe Oyj has signed a Memorandum of Understanding with ICON Advanced Co. Ltd, a Saudi Limited Liability Company fully owned by Salem Balhamer Holding. Valoe and ICON are planning to form a Joint Venture Company where ICON has a 60% and Valoe a 40% ownership. The Joint Venture Company is planning to build in Saudi Arabia a Back Contact Solar Module manufacturing plant that Valoe would engineer, build, and deliver. The planned investment is approximately EUR 15 million including a solar module manufacturing plant, technology transfer, training, and initial operation delivered by Valoe. The estimated value of Valoe’s delivery is approximately EUR 12 million. Valoe’s maximum investment is EUR 6 million. The Memorandum of Understanding is still at this stage...

Continue reading

Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results

New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021 VERVE-101 IND-Enabling Studies Ongoing to Support Planned IND Submission in 2022 Successful $306.7 Million IPO Completed to Enable Advancement of Gene Editing Programs for Cardiovascular Disease CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline and business highlights and second quarter 2021 financial results. “Verve is committed to advancing medicines that can fundamentally change treatment for patients with cardiovascular disease and ultimately, prevent it altogether,” said Sekar...

Continue reading

BurgerFi Reports Second Quarter 2021 Results

Total Revenue Increased 65% Year-Over-Year, System-wide Sales Up 63% and Same Store Sales Up 39% in Corporate Owned Restaurants Corporate-Owned Restaurant Same Store Sales Exceed 2019 Levels Digital Channel Sales Increase 12% Year-Over-Year Conference Call today, August 12, at 8:30 a.m. ET PALM BEACH, Fla., Aug. 12, 2021 (GLOBE NEWSWIRE) —  BurgerFi International Inc. (Nasdaq: BFI, BFIIW) (“BurgerFi” or the “Company”), one of the nation’s fastest-growing premium fast-casual concepts, Fast Casuals’ #1 Brand of the Year for 2021 in the Top 100 Movers and Shakers list and the top fast casual better burger chain in USA Today’s 10 Best Readers’ Choice award winner for 2021 today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Key Metrics1 Summary(in thousands, except for percentage data) Three...

Continue reading

Sotherly Hotels Inc. Reports Financial Results for the Second Quarter Ended June 30, 2021

WILLIAMSBURG, Va., Aug. 12, 2021 (GLOBE NEWSWIRE) — Sotherly Hotels Inc. (NASDAQ: SOHO), (“Sotherly” or the “Company”), a self-managed and self-administered lodging real estate investment trust (a “REIT”), today reported its consolidated results for the second quarter ended June 30, 2021. The Company’s results include the following*:  Three Months Ended     Six Months Ended    June 30, 2021     June 30, 2020     June 30, 2019     June 30, 2021     June 30, 2020     June 30, 2019    ($ in thousands except per share data)     ($ in thousands except per share data)  Total Revenue $ 34,383     $ 5,294     $ 51,541     $ 57,019     $ 42,502     $ 98,931  Net loss attributable to common stockholders   (2,811 )     (17,125 )     (732 )     (11,876 )     (31,448 )     (2,385 )                                               EBITDA   9,006       (6,637 )     12,006       12,296       (5,031 )     23,168  Hotel...

Continue reading

InfuSystem Reports Second Quarter 2021 Financial Results

Launched Fourth ITS Therapy – LymphedemaAnnounced $20 million Stock Repurchase ProgramUpdates Guidance for 2021 ROCHESTER HILLS, Michigan, Aug. 12, 2021 (GLOBE NEWSWIRE) — InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2021. 2021 Second Quarter Overview:Net revenues totaled $24.8 million, a decrease of 4% vs. prior year and up 2% sequentially.ITS net revenue was $16.3 million, an increase of 5% vs. prior year. DME Services net revenue was $8.5 million, a decrease of 18% vs. prior year.Pain Management and Negative Pressure Wound Therapy (“NPWT”) combined net revenues...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.